43706 Federal Register / Vol. 74, No. 165 / Thursday, August 27, 2009 / Notices 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel 

Economic Studies of Health Insurance 

Coverage on Drug Abuse Treatment. 

Date: September 23, 2009. 

Time: 1:30 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6101 

Executive Boulevard, Rockville, MD 20852. 

(Telephone Conference Call) 

Contact Person: Meenaxi Hiremath, PhD, 

Health Scientist Administrator, Office of 

Extramural Affairs, National Institute on 

Drug Abuse, National Institutes of Health, 

DHHS, 6101 Executive Blvd., Suite 220, MSC 

8401, Bethesda, MD 20892, 301–402–7964, 

mh392g@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Initial Review Group, Health 

Services Research Subcommittee. 

Date: October 6–7, 2009. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Madison Hotel, 1177 15th St., 

NW., Washington, DC 20005. 

Contact Person: Meenaxi Hiremath, PhD, 

Health Scientist Administrator, Office of 

Extramural Affairs, National Institute on 

Drug Abuse, National Institutes of Health, 

DHHS, 6101 Executive Blvd., Suite 220, MSC 

8401, Bethesda, MD 20892, 301–402–7964, 

mh392g@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Initial Review Group, Training 

and Career Development Subcommittee. 

Date: November 3–5, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Ritz Carlton Hotel, 1150 22nd Street, 

NW., Washington, DC 20037. 

Contact Person: Eliane Lazar-Wesley, PhD, 

Health Scientist Administrator, Office of 

Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, 6101 Executive 

Boulevard, Room 220, MSC 8401, Bethesda, 

MD 20892–8401, 301–451–4530, 

el6r@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.279, Drug Abuse and 

Addiction Research Programs, National 

Institutes of Health, HHS) 

Dated: August 20, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–20633 Filed 8–26–09; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–N–0667] 

[FDA 09–209–RH–03MOU] 

Memorandum of Understanding 

Between the Food and Drug 

Administration, National Center for 

Toxicological Research, and the Air 

Force Research Laboratory, 711 

Human Performance Wing, Human 

Effectiveness Directorate, Biosciences 

and Protection Division, for Toxicity of 

Nanomaterials 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is providing 

notice of a memorandum of 

understanding (MOU) between FDA and 

the Air Force Research Laboratory. This 

Memorandum of Understanding (MOU) 

between the Food and Drug 

Administration, National Center for 

Toxicological Research (NCTR), and the 

Air Force Research Laboratory, 711 

Human Performance Wing, Human 

Effectiveness Directorate, Biosciences 

and Protection Division, Applied 

Biotechnology Branch (711 HPW/RHPB) 

(hereinafter referred to as ‘‘the Parties’’), 

sets forth the agreement of the Parties to 

facilitate information sharing in the area 

of toxicogenomic and computational 

toxicology research. Through the 

exchange of information, the Parties 

intend to coordinate research efforts so 

as to identify and expedite research and 

development of new tools and 

technologies that can be implemented 

that promote new understanding of the 

mechanisms of biological responses to 

environmental stressors, including toxic 

injury, and to identify biomarkers of 

exposure and disease that can be used 

to improve and protect human health. 

DATES: The agreement became effective 

July 28, 2009. 

FOR FURTHER INFORMATION CONTACT: 

Points of Contact: The following are 

Responsible Officers in NCTR and 711 

HPW/RHP: 

(1) For NCTR: William Slikker, Jr., 

Director, National Center for 

Toxicological Research, Food and Drug 

Administration, 3900 NCTR Rd., 

Jefferson, AR 72079–9501, phone: 870– 

543–7950, fax: 870–543–7576, e-mail: 

william.slikker@fda.hhs.gov. 

(2) For 711 HPW/RHPB: John J. 

Schlager, Chief, Applied Biotechnology 

Branch, 2729 R St., Wright-Patterson 

AFB, OH 45433–5707, phone: 937–904– 

9570, fax: 937–255–1474, e-mail: 

john.schlager@wpafb.af.mil. 

Points of Contact: The following are 

Principal Investigators in NCTR and 711 

HPW/RHP: 

(1) For NCTR: Syed F. Ali, Senior 

Biomedical Research Scientist, National 

Center for Toxicological Research, Food 

and Drug Administration, 3900 NCTR 

Rd., Jefferson, AR 72079–9501, phone: 

870–543–7123, fax: 870–543–7745, email: syed.ali@fda.hhs.gov. 

(2) For 711 HPW/RHPB: Saber M. 

Hussain, Scientist, Group Lead, 

Biological Interaction of Nanomaterials, 

2729 R St., Wright-Patterson AFB, OH 

45433–5707, phone: 937–904–9517, fax: 

937–904–9610, e-mail: 

saber.hussain@wpafb.af.mil. 

Points of Contact: The following are 

points of contact for Agreement 

Administration in NCTR and 711 HPW: 

(1) For NCTR: Thomas J. Flammang, 

Deputy Director, Office of Research, 

National Center for Toxicological 

Research, Food and Drug 

Administration, 3900 NCTR Rd., 

Jefferson, AR 72079–9501, phone: 870– 

543–7291, fax: 870–543–7576, e-mail: 

thomas.flammang@fda.hhs.gov. 

(2) For 711 HPW/XPO: James D. 

Kearns, Technology Transfer Manager, 

2610 Seventh St., Wright-Patterson AFB, 

OH 45433–7901, phone: 937–255–3765, 

fax: 937–255–7215, e-mail: 

jim.kearns@wpafb.af.mil. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 20.108(c), 

which states that all written agreements 

and MOUs between FDA and others 

shall be published in the Federal 

Register, the agency is publishing notice 

of this MOU. 

Dated: August 18, 2009. 

David Horowitz, 

Assistant Commissioner for Policy. 

BILLING CODE 4160–01–S 

mstockstill on DSKH9S0YB1PROD with NOTICES

Federal Register / Vol. 74, No. 165 / Thursday, August 27, 2009 / Notices 43707 


mstockstill on DSKH9S0YB1PROD with NOTICESEN27AU09.192</GPH>
43708 Federal Register / Vol. 74, No. 165 / Thursday, August 27, 2009 / Notices 


mstockstill on DSKH9S0YB1PROD with NOTICESEN27AU09.193</GPH>
Federal Register / Vol. 74, No. 165 / Thursday, August 27, 2009 / Notices 43709 


mstockstill on DSKH9S0YB1PROD with NOTICESEN27AU09.194</GPH>
43710 Federal Register / Vol. 74, No. 165 / Thursday, August 27, 2009 / Notices 


mstockstill on DSKH9S0YB1PROD with NOTICESEN27AU09.195</GPH>
Federal Register / Vol. 74, No. 165 / Thursday, August 27, 2009 / Notices 43711 


mstockstill on DSKH9S0YB1PROD with NOTICESEN27AU09.196</GPH>
43712 Federal Register / Vol. 74, No. 165 / Thursday, August 27, 2009 / Notices 


mstockstill on DSKH9S0YB1PROD with NOTICESEN27AU09.197</GPH>
Federal Register / Vol. 74, No. 165 / Thursday, August 27, 2009 / Notices 43713 

[FR Doc. E9–20634 Filed 8–26–09; 8:45 am] 

BILLING CODE 4160–01–C 


mstockstill on DSKH9S0YB1PROD with NOTICESEN27AU09.198</GPH>